ZÉLL-V is organising the 12th Global Symposium on Cellular Therapy in partnership with the International Association for Organ and Stem Cell Therapy Specialists Switzerland, Germany and France (IAOSS) and German-France Society for Thymus Therapy (GFSTT) at ZÉLL-V Wellness Hub in the month of October 2019.
This global symposium will bring together cellular therapy experts working in different sub-specialties and at different scales to share data, discuss ideas and address the biggest fundamental and translation questions in the field of cellular therapy today.
ZÉLL-V cellular therapy originates from Germany and Switzerland and is clinically certificated by IAOSS and GFSTT.
ZÉLL-V has organised numerous symposiums and seminars in many countries over the last 12 years with the aim of promoting Cellular Therapy in order to help people achieve optimal health.
Following the success of previous events, we look forward to spread ZÉLL-V’s culture of health to all corners of the world so that everyone can enjoy good health and quality life.
“What we strive for, is not only to give more years to life but to give more life to years.”
Dr Michael Männel is a renowned medical specialist in Cellular Therapy and Molecular Biology. With over 40 years’ experience, he has been working intensively on organ cell therapy and its immunological detection.
Dr Michael Männel completed his medical studies at Westphalian Wilhelm University of Münster in 1968. After his graduation, he practiced in various hospitals for internal medicine and accident surgery and was a professional specialist for general medicine and occupational accidents. In 1974, he started his own practice with gastroenterological, accident-surgical, naturopathic and especially oncological complementary alignment.
Dr Michael Männel equipped himself with vast experience in knee injury/pain, ENT, degenerative diseases, chronic fatigue syndrome and carcinoma. He is also an outstanding naturopathic, internist and complementary oncologist. He personally conducted countless lectures in many large cities of Germany, the Netherlands and Austria, as well as in London and Dubai. In addition, he offered worldwide consultation of cellular therapy since 2002.
He has many publications about xenogenic organo-therapies (multiple), laser applications, positive bioenergetic influences by means of bioresonance, Paul Schmidt at MGUS (monoclonal gammopathy unclear significance, the precursor/precancerous disease of the multiple myeloma). He is also the author for “Angewandte Onko-Immunologie” (1st edition 2003, 6th edition 2008), “Therapy-Fibers of Xenogenic Organo- Peptides” (1st edition 2015, 2nd edition 2016) and “Therapy Guide of Xenogenic Organo-cell Therapies – Special for Asia and the Middle East” (1st edition 2017).
Building on strong academic background in Radiobiology & Clinical Medicine, Prof Dr Harry Yeo now is a widely respected clinician cum scientist working in the fields of Cellular Biology & Sciences, Cellular Therapeutics and Preventive Medicine, with special interests in anti-aging and regenerative medicine.
Prof Dr Harry Yeo practices cell therapy which has repair & rejuvenate properties, to help his patients to alleviate symptoms and signs of premature aging, against chronic degenerative diseases, and to recover their vigour& vitality. He also utilizes thymus and various organ cell extracts to boost up immune system to achieve cancer preventive.
He is the first in the medical world to suggest the causal link between “Suboptimal Health Conditions” and “Chronic Inflammation”, and their complexly intertwined pathophysiological mechanisms. He will be establishing the first ever ZÉLL-V clinical research unit in Asia, the First in the world focusing on Southeast Asians.
Presently, Prof Dr Harry Yeo is the Head of Medical Unit of ZÉLL-V in Asia region, overseeing the overall medical and clinical operations and development of latest medical innovations.
Dato’ Dr. Nor Shahidah Khairullah obtained her medical degree from the University of Malaya in 1983 and continued her post graduate education in Clinical and Molecular Virology at University of London’s School of Tropical Medicine and Hygiene in the United Kingdom. After her Masters in Clinical Virology in 1987, she was offered the British Commissioner’s Research award for her work in Dengue vaccines.
She is a member of the International Association for Stem Cell Therapy Specialist Switzerland, Germany and France (IAOSS) and the German-France Society for Thymus Therapy (GFSTT) for more than 10 years. She qualified as a Member of the Royal College of Pathologist (MRCPath) in 1994 and was awarded a Fellowship from The Royal College ( FRCPath) in 1996.
In addition to this, she is a Fellow of the Academy of Medicine Malaysia (FAMM).
In 1998, she became the Chief Executive Officer of the Malaysian Liver Foundation, a non-profit organisation dedicated to the study of hepatobiliary diseases and liver cancer through education, research and training.
She was a member of the Technical Advisory Board for the Drugs for Neglected Diseases Initiative (DNDi) in Geneva, Switzerland for the past 6 years and was also a regional adviser representing the Ministry of Health for the World Health Organization (WHO) and European Commission (EU) between 2002 until 2007.
In 2002, she started her work in cell therapy and later visited Dr Ben Pfeifer in Aeskulap Clinic , a Centre for Holistic Medicine in Brunnen Switzerland.
In 2007 , she was awarded the Royal Award, Dato Paduka Mahkota Perak by the Sultan of Perak for her work in the field of medicine.